Nectin Therapeutics Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Holding
- Established
- 2017-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.nectintx.com
A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab
Phase 1
Recruiting
- Conditions
- Tumor, SolidMetastatic CancerCancerAdvanced Solid TumorLocally Advanced Solid Tumor
- Interventions
- Drug: NTX-1088Drug: Pembrolizumab
- First Posted Date
- 2022-05-18
- Last Posted Date
- 2024-01-29
- Lead Sponsor
- Nectin Therapeutics Ltd
- Target Recruit Count
- 90
- Registration Number
- NCT05378425
- Locations
- 🇺🇸
Ochsner Clinic Foundation, New Orleans, Louisiana, United States
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sheba Medical Center, Ramat Gan, Israel
© Copyright 2025. All Rights Reserved by MedPath